R&D FOR BEHAVIOR CHANGE Collaborative development to automate and assess digital health interventions.

JOIN THE DISCUSSION ON BEHAVIOR CHANGE

Learn about our views on agile science, evidence-building, patient adherence and behavior change technologies.

BLOG

The Clinical and Economic Burden to Managed Care Organizations of Poor Medication Compliance in Cardiovascular Disease Risk and Diabetes, the role of MEMOTEXT

  • October 2014

Summary: The clinical and economic burdens of patient non-compliance are well established, driven by broad chronic disease states such as cardiovascular diseases and diabetes. The economic impact of patient non-compliance is borne by managed care organizations through wasted pharmacy dispensing and the additional costs incurred from poor clinical outcomes. Adding to this cost is the lost opportunity to improve Medicare STAR ratings and PPACA identified quality measurements, several of which are specific to management of diabetes and hypertension, where patient compliance is a considerable challenge.

Patient non-compliance has multiple rationales. Health systems have tried different modalities to improve compliance, but historical efforts have resulted in limited success. Traditional compliance improvement modalities are either not individualized to the patient or are not economically feasible for large populations. Improving medication compliance through the use of technology integrated with behavioral health evidence has advanced to engage individual patients and personalized compliance communications are a solution. One technology is the MEMOTEXT Personalized Adherence Solutions, addressing the unmet need to individualize patient communication with proven results.

 

Back to Top